

1 July 2025

Our Ref: FOI 1218

Dear

**Freedom of Information Act 2000
Information in Relation to Oncology Breast Cancer**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above, which you requested on 3 June 2025.

A response to the questions you have raised has been provided by the Surgery Elective Maternity and Paediatrics Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Olivia Robinson
Information Governance Officer

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies listed in Table 1?

A1. Please see Table 1 below, for the number of patients that have been treated for breast cancer (any stage) in the past 3 months with the listed systemic anti-cancer therapies.

Table 1

Systemic Anti-cancer Therapy	Number of Patients
Abemaciclib & Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	16
Abemaciclib & Fulvestrant	Nil
Alpelisib + Fulvestrant	Nil
Anthracycline (e.g. doxorubicin or epirubicin) & Cyclophosphamide	19
Anthracycline (e.g. doxorubicin or epirubicin) & Cyclophosphamide + Paclitaxel	6
Atezolizumab	Nil
Capivasertib	1
Capecitabine as a single agent	7
Carboplatin + Paclitaxel	Nil
Elacestrant	Nil
Eribulin as a single agent or in combination	6
Everolimus & Exemestane	Nil
Fulvestrant as a single agent	15
Palbociclib & Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	20
Palbociclib & Fulvestrant	7
Parp Inhibitors (Olaparib/Talazoparib)	Nil
Pembrolizumab Monotherapy	Nil
Anthracycline (e.g. doxorubicin or epirubicin) & Cyclophosphamide & Pembrolizumab	6
Carboplatin & Paclitaxel & Pembrolizumab	Nil
Pertuzumab (Perteja) & Trastuzumab (Herceptin)	1
Phesgo (Pertuzumab + Trastuzumab in a single injection)	21

Ribociclib & AromataseInhibitor (e.g. anastrozole, exemestane, letrozole)	3
Ribociclib & Fulvestrant	1
Sacituzumab Govitecan	3
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as A single agent	8
Trastuzumab deruxtecan (Enhertu)	5
Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel	31
Trastuzumab emtansine (Kadcyla)	5
Any other active systemic anti-cancer therapy	8

Please note, with regards to the systemic anti-cancer therapy 'Aromatase Inhibitor as a single agent' the Trust is not able to provide a figure as this is managed between secondary and primary care.

Q2. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

A2. The Trust does not participate in any clinical trials for breast cancer.